ArticleScience China. Life sciences2026
A potent human neutralizing antibody targeting the receptor-binding site in the glycoprotein gp350 of Epstein-Barr virus.
Article in Science China. Life sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The Epstein-Barr virus (EBV) is associated with multiple lymphoid malignancies and autoimmune diseases. The glycoprotein gp350, the most abundant envelope protein on the EBV virion surface, has been the primary target for the vaccine design. However, all the attempts have failed to prevent asymptomatic infection in clinical trials. This setback highlights an incomplete understanding of the immune response to gp350 and emphasizes the need for more comprehensive antibody studies. Here, we identified three human-derived anti-gp350 monoclonal antibodies from a nonimmune human scFv library. Of these, the S54 antibody exhibited a potent neutralizing activity against virus infection of Raji B cells. Using cryo-EM, we resolved the structure of the S54-gp350 complex, revealing that the S54 epitope substantially overlaps with the CR2 recognition site. Our findings elucidate the molecular mechanism by which anti-gp350 antibodies block EBV infection of B cells in vitro, providing valuable insights for antibody-based therapy and vaccine development.
Indexed as
Identifiers
41843376What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.